CLLS Stock Summary and Trading Ideas (Cellectis S.A. - American Depositary Shares | NASDAQ:CLLS)

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.

As of November 12, 2026, CLLS stock price declined to $1.35 with 21,048 million shares trading.

CLLS has a beta of 1.95, meaning it tends to be more sensitive to market movements. CLLS has a correlation of 0.06 to the broad based SPY ETF.

CLLS has a market cap of $135.94 million. This is considered a Micro Cap stock.

Last quarter Cellectis S.A. - American Depositary Shares reported $7 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.07.

In the last 3 years, CLLS traded as high as $5.48 and as low as $.88.

The top ETF exchange traded funds that CLLS belongs to (by Net Assets): IBB.

CLLS has underperformed the market in the last year with a return of -63.7%, while the SPY ETF gained +12.5%. In the last 3 month period, CLLS fell short of the market, returning -53.3%, while SPY returned -1.0%. However, in the most recent 2 weeks CLLS has outperformed the stock market by returning +7.1%, while SPY returned -1.5%.

CLLS support price is $1.25 and resistance is $1.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS shares will trade within this expected range on the day.